This trial is evaluating whether rilzabrutinib will improve 2 primary outcomes and 5 secondary outcomes in patients with Warm Autoimmune Hemolytic Anemia (wAIHA). Measurement will happen over the course of By Week 24 in Part A.
This trial requires 20 total participants across 1 different treatment group
This trial involves a single treatment. Rilzabrutinib is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.
"In the pediatric population, multiple cases have been noted to have been treated with iron dextran solutions. There have also been numerous cases that have been treated with iron gluconate solution. These cases were most commonly associated with anemia resulting from an infectious process (blood stream, malaria). Iron gluconate is more widely available and is more expensive.\n" - Anonymous Online Contributor
"About 13,000 people are diagnosed with anemia and 1,800 of those are diagnosed with hemolytic anemia annually. About 25 million adult Americans have one or more anemia-related blood disorders. These disorders affect about 13 million adults yearly." - Anonymous Online Contributor
"Anemia, specifically, erythrocyte hemolytic anemia is the most common form of anemia, and thus, there is an increased risk of hemolysis at any given serum iron level. Hgb is the only parameter helpful to monitor anemia and determine severity." - Anonymous Online Contributor
"Anemia and hemolytic is curable. The treatment is not surgical but a therapy of anemia and control of hemolysis of the blood circulation system. Anemia is the result of various factors the only one being hemoglobin." - Anonymous Online Contributor
"In this series, signs of abnormal hemoglobin levels (Hgb < 11 pg/L) in children with leukemia were present in 25% of patients. This finding indicates that the Hgb level should be monitored in both children and adults with leukemia. The prevalence of abnormal Hgb in those of all ages in this series supports the recommendation that the Hgb level should be routinely checked in all children with acute myeloid leukemia to ensure early detection and treatment." - Anonymous Online Contributor
"Hemolytic causes are a common source of anemia in patients treated for hemostatic diseases. The most frequent cause of hemolytic anemia in patients treated with oral anticoagulants is anemia induced as a complication of anti-phospholipid or anti-glycoprotein IIb/IIIa antibody-associated hemolytic disorders." - Anonymous Online Contributor
"Almost one in four patients are diagnosed at the time of a diagnosis of anemia, hemolytic. While this is not surprising, the incidence of the disease depends upon the population being studied. Most studies show a high incidence of iron deficiency in this population. The age of anemia diagnosed usually is between the ages of 20 to 60 years." - Anonymous Online Contributor
"In a recent study, findings reveals a positive impact of RILZB on HRQoL in AE in clinical practice. We propose RILZB as a potential treatment of anemia." - Anonymous Online Contributor
"A number of causes of anemia must be evaluated: dietary intake, environmental contaminants, infectious or malignant involvement of the gastrointestinal tract. Hemolysis must always be considered in the differential diagnosis of anemia and its causes. Hemag/oinemia is an infrequently reported disease entity but is best known as a complication of sickle-cell anemia. More than half of all hemolytic anemias are not well defined. Further investigation is needed to refine our understanding of hemolytic anemias." - Anonymous Online Contributor
"Recent findings confirms the existence of a high familial risk of anemia and/or acute hemolytic diseases in this population, thus suggesting this disease to be genetically regulated. The observation of the presence of the HPA-1b allele suggests the existence of a predisposing factor. The data obtained from this study may contribute to a better understanding of the heterogeneity of the condition." - Anonymous Online Contributor
"Rilzabrutinib exerts antitumor effects against both HSPC and LPD, although the mechanism is still unclear. Combination treatment with rilzabrutinib may be an effective strategy to treat refractory LPD." - Anonymous Online Contributor
"Rilzabrutinib is a novel, oral, small molecule, kinase inhibitor specifically inhibiting Janus kinases (JAK) 1 and 2, with high selectivity and potency against other tyrosine kinases, including erythropoietin receptor (EPO-R) and insulin receptor (IR). It has strong anti-proliferative activity and inhibits erythropoiesis [increase in hemoglobin concentration] in vitro and in rodent models as well as in clinical trials. Moreover, rilzabrutinib is efficacious and well tolerated in patients with chronic erythropoietic failure receiving regular rHuEPO." - Anonymous Online Contributor